Baird Starts Audentes Therapeutics (BOLD) at Underperform
Tweet
Share
E-mail
Get Alerts BOLD Hot Sheet
Price: $2.83 --0%
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Join SI Premium – FREE
Baird analyst Madhu Kumar initiates coverage on Audentes Therapeutics (NASDAQ: BOLD) with a Underperform rating and a price target of $10.00.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $26.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Chardan Starts Odysight.AI Inc. (ODYS) at Buy
- Truist Securities Reinstates Pacira Pharmaceuticals (PCRX) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
